StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson rYBREVANT / LAZCLUZE (amivantamab / lazertinib) — International sales ($M) ($M)

Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule

QuarterlyAnnual
Latest, Q3 2026
119
Period ended Sep 30, 2026
Change on a year earlier
+95.1%
61 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
7
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRYBREVANT / LAZCLUZE (amivantamab / lazertinib) — International sales ($M) ($M)Year on yearSource
Q3 2026Sep 30, 2026119+95.1%Form 10-Q (filed 2026-10-21) ↗
Q2 2026Jun 28, 202699+141.5%Form 10-Q (filed 2026-07-23) ↗
Q1 2026Mar 29, 202682+192.9%Form 10-Q (filed 2026-04-22) ↗
Q4 2025Dec 28, 202570+233.3%Form 10-K (filed 2026-02-11) ↗
Q3 2025Sep 28, 202561+190.5%Form 10-Q (filed 2026-10-21) ↗
Q2 2025Jun 29, 202541+141.2%Form 10-Q (filed 2026-07-23) ↗
Q1 2025Mar 30, 202528+154.5%Form 10-Q (filed 2026-04-22) ↗
Q4 2024Dec 29, 202421–Form 10-K (filed 2026-02-11) ↗
Q3 2024Sep 29, 202421–Form 10-Q (filed 2025-10-22) ↗
Q2 2024Jun 30, 202417–Form 10-Q (filed 2025-07-24) ↗
Q1 2024Mar 31, 202411–Form 10-Q (filed 2025-04-23) ↗

Cite this data

StockData. (2026). Johnson & Johnson RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — International sales ($M) ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_rybrevant_intl

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.